Amylyx Pharmaceuticals (AMLX)
(Delayed Data from NSDQ)
$2.09 USD
-0.07 (-3.24%)
Updated Sep 4, 2024 04:00 PM ET
After-Market: $2.10 +0.01 (0.48%) 7:58 PM ET
5-Strong Sell of 5 5
F Value C Growth F Momentum F VGM
Balance Sheet
Fiscal Year End for Amylyx Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 371 | 347 | 96 | 13 | -99,999 |
Receivables | 40 | 15 | 0 | 0 | NA |
Notes Receivable | 0 | 0 | 0 | 0 | NA |
Inventories | 38 | 10 | 0 | 0 | NA |
Other Current Assets | 15 | 10 | 9 | 1 | NA |
Total Current Assets | 465 | 382 | 105 | 14 | NA |
Net Property & Equipment | 3 | 3 | 0 | 0 | NA |
Investments & Advances | 0 | 0 | 0 | 0 | NA |
Other Non-Current Assets | 45 | 0 | 0 | 0 | NA |
Deferred Charges | 0 | 0 | 0 | 0 | NA |
Intangibles | 0 | 0 | 0 | 0 | NA |
Deposits & Other Assets | 1 | 1 | 0 | 0 | NA |
Total Assets | 517 | 391 | 106 | 14 | NA |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | NA |
Accounts Payable | 22 | 6 | 4 | 4 | NA |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | NA |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | NA |
Accrued Expenses | 58 | 38 | 13 | 4 | NA |
Income Taxes Payable | 0 | 0 | 0 | 0 | NA |
Other Current Liabilities | 0 | 0 | 0 | 0 | NA |
Total Current Liabilities | 82 | 47 | 17 | 7 | NA |
Mortgages | 0 | 0 | 0 | 0 | NA |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | NA |
Convertible Debt | 0 | 0 | 0 | 0 | NA |
Long-Term Debt | 0 | 0 | 0 | 1 | NA |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | NA |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | NA |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | NA |
Total Liabilities | 84 | 51 | 17 | 9 | NA |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 239 | 72 | NA |
Common Stock (Par) | 0 | 0 | 0 | 0 | NA |
Capital Surplus | 738 | 695 | 5 | 1 | NA |
Retained Earnings | -305 | -354 | -156 | -68 | NA |
Other Equity | 0 | 0 | 0 | 0 | NA |
Treasury Stock | 0 | 0 | 0 | 0 | NA |
Total Shareholder's Equity | 433 | 341 | 88 | 5 | NA |
Total Liabilities & Shareholder's Equity | 517 | 391 | 106 | 14 | NA |
Total Common Equity | 433 | 341 | -151 | -67 | 0 |
Shares Outstanding | 67.50 | 66.20 | 56.40 | NA | NA |
Book Value Per Share | 6.42 | 5.15 | -2.68 | 0.00 | 0.00 |
Fiscal Year End for Amylyx Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 310 | 373 | 371 | 355 | 357 |
Receivables | 4 | 20 | 40 | 29 | 33 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 38 | 32 | 25 |
Other Current Assets | 13 | 17 | 15 | 17 | 12 |
Total Current Assets | 327 | 411 | 465 | 434 | 427 |
Net Property & Equipment | 1 | 2 | 3 | 3 | 3 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 45 | 24 | 18 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 1 | 1 | 1 | 1 | 1 |
Total Assets | 332 | 417 | 517 | 467 | 454 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 5 | 21 | 22 | 6 | 25 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 63 | 68 | 58 | 37 | 37 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 70 | 92 | 82 | 46 | 64 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 71 | 93 | 84 | 48 | 67 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 758 | 748 | 738 | 728 | 717 |
Retained Earnings | -496 | -424 | -305 | -310 | -331 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 261 | 324 | 433 | 418 | 386 |
Total Liabilities & Shareholder's Equity | 332 | 417 | 517 | 467 | 454 |
Total Common Equity | 261 | 324 | 433 | 418 | 386 |
Shares Outstanding | 68.00 | 68.00 | 67.50 | 67.30 | 67.10 |
Book Value Per Share | 3.84 | 4.77 | 6.42 | 6.22 | 5.76 |